Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry-Reference-Cited by-同舟云学术

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Published:2022-05-29 Issue:6 Volume:33 Page:2827-2837
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Kojanova Martina¹^ORCID,Hugo Jan²,Velackova Barbora³,Cetkovska Petra⁴,Fialova Jorga¹,Dolezal Tomas³,Tichy Martin⁵,Gkalpakiotis Spyridon²^ORCID

Affiliation:

1. Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic

2. Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic

3. Value Outcomes, Prague, Czech Republic

4. Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic

5. Department of Dermatology and Venereology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic

Funder

Charles University Research Program Cooperation 34 – Internal Disciplines

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2022.2082354

Reference39 articles.